ArticleLipids in health and disease2025
Age-multiplied low density lipoprotein cholesterol (LDL-C) burden (AM-LDL) index stratifies bleeding and ischemic risk in acute coronary syndrome: implications for early therapeutic intensification.
Article in Lipids in health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundEarly identification of high-risk individuals after Acute Coronary Syndrome (ACS) is critical for tailoring intensive lipid-lowering therapy, a cornerstone of secondary prevention to alleviate the growing global burden of cardiovascular diseases, while practical tools integrating lipid burden and vascular aging remain lacking. This study proposes the age-multiplied low density lipoprotein cholesterol (LDL-C) burden (AM-LDL) index to quantify cumulative atherogenic exposure and stratify 1-year ischemic and bleeding risk.
methodsThis post-hoc analysis utilized data from the prospective "Beijing Risk Intervention Clinical (BRIC) Study", which enrolled post-percutaneous coronary intervention (PCI) ACS patients from a 30-center Chinese cohort and followed them for one year. AM-LDL was calculated by multiplying the admission LDL-C concentration by the patient's age. Study endpoints comprised Bleeding Academic Research Consortium (BARC) type ≥ 2 bleeding, major adverse cardiovascular events (MACE), and net adverse clinical events (NACE).
resultsAmong the 5658 participants, 309 experienced BARC ≥ 2 bleeding event, 156 had MACE, and 454 developed NACE. AM-LDL showed a significant association with MACE and NACE in Kaplan-Meier analysis (log-rank P = 0.002 for each), in contrast to bleeding (P = 0.055). Subsequent multivariable Cox modeling sustained its independent association with MACE (Hazard Ratio [HR] = 2.623, 95% Confidence Interval [95%CI]: 1.411-4.876, P = 0.002) and NACE (HR = 1.520, 95% CI: 1.094-2.111, P = 0.012), but not with bleeding (HR = 1.203, 95% CI: 0.815-1.775, P = 0.353). Restricted cubic spline analysis revealed a linear dose-response relationship, and an inverted U-shaped association with NACE, while no nonlinear correlation was detected for bleeding.
conclusionThe AM-LDL index, derived from two readily available admission parameters, is associated with post-discharge one-year MACE and NACE risks among ACS patients. Its application may help improve risk stratification, allowing for timely treatment intensification and a more personalized prevention strategy, while warranting validation in interventional trials before clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.